Disulfiram: Mechanisms, Applications, and Challenges

Author:

Lanz Jenna1,Biniaz-Harris Nicholas1,Kuvaldina Mara1,Jain Samta2,Lewis Kim2,Fallon Brian A.13

Affiliation:

1. Lyme & Tick-Borne Diseases Research Center, Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, Columbia University, New York, NY 10032, USA

2. Antimicrobial Discovery Center, Department of Biology, Northeastern University, Boston, MA 02115, USA

3. New York State Psychiatric Institute, New York, NY 10032, USA

Abstract

Background: Since disulfiram’s discovery in the 1940s and its FDA approval for alcohol use disorder, other indications have been investigated. This review describes potential clinical applications, associated risks, and challenges. Methods: For this narrative review, a PubMed search was conducted for articles addressing in vivo studies of disulfiram with an emphasis on drug repurposing for the treatment of human diseases. The key search terms were “disulfiram” and “Antabuse”. Animal studies and in vitro studies highlighting important mechanisms and safety issues were also included. Results: In total, 196 sources addressing our research focus spanning 1948–2022 were selected for inclusion. In addition to alcohol use disorder, emerging data support a potential role for disulfiram in the treatment of other addictions (e.g., cocaine), infections (e.g., bacteria such as Staphylococcus aureus and Borrelia burgdorferi, viruses, parasites), inflammatory conditions, neurological diseases, and cancers. The side effects range from minor to life-threatening, with lower doses conveying less risk. Caution in human use is needed due to the considerable inter-subject variability in disulfiram pharmacokinetics. Conclusions: While disulfiram has promise as a “repurposed” agent in human disease, its risk profile is of concern. Animal studies and well-controlled clinical trials are needed to assess its safety and efficacy for non-alcohol-related indications.

Funder

FDC Foundation

Steven and Alexandra Cohen Foundation

Lyme and Tick-Borne Diseases Research Center at the Columbia University Irving Medical Center

Columbia University Vagelos College of Physicians and Surgeons

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Pharmacology, Toxicology and Pharmaceutics,Biochemistry,Microbiology

Reference196 articles.

1. From Disulfiram to Antabuse: The Invention of a Drug;Kragh;Bull. Hist. Chem.,2008

2. Tracing the Journey of Disulfiram: From an Unintended Discovery to a Treatment Option for Alcoholism;Pal;J. Ment. Health Hum. Behav.,2015

3. The Status of Disulfiram: A Half of a Century Later;Suh;J. Clin. Psychopharmacol.,2006

4. A Drug Sensitising the Organism to Ethyl Alcohol;Hald;Lancet,1948

5. The Efficacy of Disulfiram: A Review of Outcome Studies;Hughes;Addict. Abingdon Engl.,1997

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3